This invention provides compositions comprising a protein and an absorption enhancer, methods for treating inflammatory disorders, such as irritable bowel disease (IBD) comprising administering same, and methods for oral, intra-rectal, or other gut-related administration of a protein with an enzymatic activity, comprising orally, intra-rectally, or other gut-related administering same.

The present invention provides compositions and methods for enhancing the health of a subject by, for example, restoring the subjects gut microbiome, increasing water and electrolyte absorption in the digestive tract, and/or providing a therapeutic substance to the subject. In certain specific embodiments, the present invention can be used for ameliorating the adverse physiological effects that can result from the presence of one or more detrimental microorganisms in a subjects gut. In certain specific embodiments, the present invention can also be used as an enhanced mode of hydration or re-hydration, particularly for subjects suffering from, for example, a condition that causes vomiting and/or diarrhea.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

A marker for determining a mental disease is provided. The marker can be used in an objective diagnosis of such a mental disease. The marker contains one or more enterobacteria of Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens, and Enterobacteriaceae.

The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.

Provided herein are methods for treating COVID-19 or associated GI symptoms with rifaximin compositions.

A method of treating diarrhea or an inflammatory condition of the gut in a subject comprises administering a therapeutically effective amount of beta-hydroxy-beta-methylbutyrate (HMB) or a salt thereof to a subject in need thereof. A method of treating secretory diarrhea in a subject comprises administering a therapeutically effective amount of HMB or a salt thereof to a subject exhibiting one or more of the following symptoms: loss of fluids from the gut, loss of electrolytes from the gut, dehydration, or inflammation of the intestinal tract.

A method of treating diarrhea or an inflammatory condition of the gut in a subject comprises administering a therapeutically effective amount of beta-hydroxy-beta-methylbutyrate (HMB) or a salt thereof to a subject in need thereof. A method of treating secretory diarrhea in a subject comprises administering a therapeutically effective amount of HMB or a salt thereof to a subject exhibiting one or more of the following symptoms: loss of fluids from the gut, loss of electrolytes from the gut, dehydration, or inflammation of the intestinal tract.

Composition and methods for treating cytokine storm and cytokine release syndrome are disclosed.

Composition and methods for treating cytokine storm and cytokine release syndrome are disclosed.